Needham Rates Taysha Gene Therapies (TSHA) buy, $12 Price Target
Needham reaffirms its Buy rating on Taysha Gene Therapies with a price target of $12, as the stock trades at $6.94, a 72.91% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Needham rated Taysha Gene Therapies, Inc. ($TSHA) "buy" with a $12 price target on June 22, 2026.
Since the rating, $TSHA is up 3.1% after 1 week, down 13.3% after 1 month and down 44.6% to date (from the $6.53 close on Jun 22, 2026).
TSHA
Taysha Gene Therapies, Inc.
Key Points
- On June 22, 2026, Needham reiterated its Buy rating on Taysha Gene Therapies, Inc. (TSHA) with a price target of $12.0.
- The stock is currently trading at $6.94, well below the target, suggesting significant upside potential.
- Taysha Gene Therapies focuses on gene therapies for severe monogenic diseases, with its next earnings report scheduled for November 4, 2026.
Get $TSHA trade alerts by text
We text you when insiders, Congress or big funds trade $TSHA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Taysha Gene Therapies, Inc. alert may contain errors. Disclosures
Needham Maintains Buy Rating
On June 22, 2026, Needham reiterated its Buy rating on Taysha Gene Therapies, Inc. (TSHA) with a price target of $12.0. The stock is currently trading at $6.94, indicating a gap that suggests potential upside for investors.
Needham vs. the S&P 500
Hypothetical returns from Needham's disclosed trades, not real profit or advice. How we model this.
Analysts Set New Price Targets
Analyst Gil Blum from Needham emphasized the company’s prospects while maintaining the same price target of $12.0. This comes as Taysha Gene Therapies continues to develop innovative gene therapies aimed at treating severe monogenic diseases of the central nervous system. The stock is currently priced significantly below the target, suggesting that analysts see considerable room for growth.
Other firms have also weighed in on Taysha Gene Therapies recently. On June 30, 2026, Needham reaffirmed its Buy rating, while Baird maintained an Outperform rating with a target of $15.0. Goldman Sachs also maintained a Buy rating, raising its target to $13.0 on July 21, 2026. Wolfe Research initiated coverage with an Outperform rating on September 17, 2026.
How Taysha Gene Therapies, Inc. Stock Has Traded
The stock has recently traded around $6.94, which is above its 52-week low of $2.87 but below its 52-week high of $7.30. The stock's performance relative to its moving averages shows it is currently above its 50-day moving average of $5.78 and its 200-day moving average of $5.48. This positioning may indicate a strengthening trend.
$TSHA price target
Taysha Gene Therapies, Inc. daily closes and this analyst's $12 target. Not advice.
Recent Earnings
Taysha Gene Therapies reported revenue of $5.49 million. The company is not currently profitable, with an EPS of -0.41. Investors will be looking forward to the next earnings report on November 4, 2026, for updates on its financial health and clinical developments.
What Taysha Gene Therapies, Inc. Does
Taysha Gene Therapies, headquartered in Dallas, Texas, is a biotechnology company focused on developing gene therapies for severe diseases affecting the central nervous system. The company’s pipeline includes treatments for conditions like giant axonal neuropathy and Rett syndrome.
What's Ahead for Taysha Gene Therapies, Inc.
As Taysha prepares for its next earnings report on November 4, 2026, investors will be watching for updates on its clinical trials and overall progress. The recent analyst ratings suggest that there is optimism about the company's future, particularly given the significant gap between the current stock price and the analysts' price targets.
Related Filing Alerts
Source: Needham's rating change on $TSHA (Jun 22, 2026). Written by software, not financial advice. How we make alerts